search
Back to results

Ertugliflozin for Functional Mitral Regurgitation (EFFORT)

Primary Purpose

Mitral Valve Insufficiency, Left Ventricular Systolic Dysfunction

Status
Active
Phase
Phase 3
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Ertugliflozin
Placebo
Sponsored by
Asan Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Mitral Valve Insufficiency

Eligibility Criteria

20 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients must agree to the study protocol and provide written informed consent
  • Outpatients ≥ 20 years of age, male or female
  • Non-diabetic or type2 DM patients with HbA1c 7.0-10.5%
  • Patients with secondary functional MR (stage B and C) and LV dysfunction

    • Symptoms due to coronary ischemia or heart failure may be present but symptoms due to MR should be absent
    • Normal mitral valve leaflets and chords
    • Regional or global wall motion abnormalities with mild or severe tethering of leaflet
    • MR whose ERO > 0.10 cm2 and which lasted > 6 months under medical treatment with a β-blocker and an ACE inhibitor (or ARB)
    • 35% < LV ejection fraction < 50%
  • Dyspnea of NYHA functional class II or III
  • Titration of HF medications should be completed and patients must take a stable, optimized dose of a β-blocker and an ACE inhibitor (or ARB) for at least 4 weeks prior to study entry

Exclusion Criteria:

  • History of hypersensitivity or allergy to the study drug, drugs of similar chemical classes, or SGLT-2 as well as known or suspected contraindications to the study drug
  • Current use or prior use of a SGLT-2 inhibitor or combined SGLT-1 and 2 inhibitor
  • Known history of angioedema
  • Any evidence of structural mitral valve disease, including prolapse of mitral leaflets and rupture of chords or papillary muscles
  • Current acute decompensated heart failure or dyspnea of NYHA functional class IV
  • Medical history of hospitalization within 6 weeks
  • Symptomatic hypotension and/or a SBP < 100 mmHg at screening
  • Estimated GFR < 45 mL/min/1.73m2
  • History of ketoacidosis
  • Evidence of hepatic disease as determined by any one of the following: AST or ALT values exceeding 2 x upper limit of normal (ULN) at screening visit (Visit 0), history of hepatic encephalopathy, history of esophageal varices, or history of portacaval shunt.
  • Acute coronary syndrome, stroke, major CV surgery, PCI within 3 months
  • Substantial myocardial ischemia requiring coronary revascularization, a plan of coronary revascularization or mitral valve intervention within 1 year
  • Indication of cardiac resynchronization therapy, a plan of heart transplantation or implantation of cardiac resynchronization therapy
  • History of severe pulmonary disease
  • Significant aortic valve disease
  • Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using a barrier method plus a hormonal method
  • Pregnant or nursing (lactating) women
  • Any clinically significant abnormality identified at the screening visit, physical examination, laboratory tests, or electrocardiogram which, in the judgment of the investigator, would preclude safe completion of the study

Sites / Locations

  • Asan Medical Center
  • Samsung Medical Center
  • Seoul National University Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

Active Comparator

Arm Label

Placebo

Ertugliflozin

Arm Description

All patients will receive placebo in addition to their usual medications. Titration of HF medications should be completed and patients must take a stable, optimized dose of a β-blocker and an ACE inhibitor (or ARB) for at least 4 weeks prior to study entry.

All patients will receive ertugliflozin 5 mg qd in addition to their usual medications. Titration of HF medications should be completed and patients must take a stable, optimized dose of a β-blocker and an ACE inhibitor (or ARB) for at least 4 weeks prior to study entry.

Outcomes

Primary Outcome Measures

Change of EROA
Change of effective regurgitant orifice area (EROA) of functional mitral regurgitation

Secondary Outcome Measures

Change of regurgitant volume
Change of regurgitant volume of functional mitral regurgitation
Change of end-systolic volume
Change of left ventricular end-systolic volume
Change of end-diastolic volume
Change of left ventricular end-diastolic volume
Change of NT-proBNP
Change of NT-proBNP (N-terminal of the prohormone brain natriuretic peptide)
Change of GLS
Change of left ventricular global longitudinal strain
Change of LA volume
Change of left atrial volume index

Full Information

First Posted
January 14, 2020
Last Updated
February 6, 2023
Sponsor
Asan Medical Center
Collaborators
Merck Sharp & Dohme LLC
search

1. Study Identification

Unique Protocol Identification Number
NCT04231331
Brief Title
Ertugliflozin for Functional Mitral Regurgitation
Acronym
EFFORT
Official Title
Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Assess the Efficacy of Ertugliflozin on Reduction of Mitral Regurgitation in Patients With Functional Mitral Regurgitation Secondary to Left Ventricular Dysfunction
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
November 4, 2020 (Actual)
Primary Completion Date
December 2023 (Anticipated)
Study Completion Date
December 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Asan Medical Center
Collaborators
Merck Sharp & Dohme LLC

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
In patients with heart failure (HF) and left ventricular (LV) dilation, adverse LV remodeling causes tethering of mitral valve (MV) preventing sufficient coaptation of normal leaflets and resulting in functional MR. Because secondary functional MR usually develops as a result of LV dysfunction, guideline-directed medical therapy for HF forms the mainstay of therapy. However, beta blockers, angiotensin-converting-enzyme (ACE) inhibitors, and angiotensin receptor blockers (ARB) fail to reverse adverse LV remodeling and functional MR, and the morbidity and mortality of patients with functional MR remain high despite standard medical therapy. Randomized trials to explore cardiovascular (CV) benefit of the sodium-glucose co-transporter-2 (SGLT2) inhibitor have been performed and showed a significant reduction on the risk of CV death or hospitalization for HF. However, its effect on cardiac structure and function was not evaluated and further mechanistic studies are needed to interpret beneficial clinical effects of the SGLT2 inhibitors. Based on studies demonstrating SGLT2 inhibitors' favorable effects on LV modeling, investigators hypothesize that SGLT2 inhibitor, ertugliflozin, is effective on improving MR in patients with functional MR secondary to LV dysfunction and try to examine this hypothesis in a multicenter, double-blind, randomized comparison study using echocardiography.
Detailed Description
In patients with heart failure (HF) and left ventricular (LV) dilation, adverse LV remodeling causes tethering of mitral valve (MV) preventing sufficient coaptation of normal leaflets and resulting in functional MR. Because secondary functional MR usually develops as a result of LV dysfunction, guideline-directed medical therapy for HF forms the mainstay of therapy. However, beta blockers, angiotensin-converting-enzyme (ACE) inhibitors, and angiotensin receptor blockers (ARB) fail to reverse adverse LV remodeling and functional MR, and the morbidity and mortality of patients with functional MR remain high despite standard medical therapy. A recent randomized trial proved that reduction of functional MR by transcatheter MV repair resulted in a lower rate of hospitalization for HF and lower mortality in patients with HF and significant secondary MR, and investigators recently demonstrated that the angiotensin receptor-neprilysin inhibitor (ARNI) is more effective in improving functional MR associated with HF than the ARB in a double-blind, randomized trial. In this trial, investigators enrolled 118 stable HF patients with functional MR, whose effective regurgitant orifice area (EROA) larger than 0.1 cm2, lasting > 6 months despite standard medical treatment, and the primary end point of change in EROA was significantly different between the ARNI group and the ARB group (-0.058±0.095 versus -0.018±0.105 cm2; P=0.032), and a decrease in end-diastolic volume index of the LV was also significantly greater in the ARNI group than in the ARB group (P=0.044). Sodium-glucose co-transporter-2 (SGLT2) inhibitors reduce cardiac preload and afterload by natriuresis and lowering arterial stiffness, similar to the neprilysin inhibitor that facilitates sodium excretion and has vasodilating effects. In addition, effects on blood pressure reduction and weight loss may ultimately have a beneficial effect on LV remodeling. Recently it has been reported that SGLT2 inhibitors have a multifaceted effect on cardiac function including improvement in endothelial dysfunction and aortic stiffness, reduction in epicardial fat accumulation as well as in visceral adipocyte hypertrophy. Randomized trials to explore cardiovascular (CV) benefit of the SGLT2 inhibitor have been performed and showed a significant reduction on the risk of CV death or hospitalization for HF. However, its effect on cardiac structure and function was not evaluated and further mechanistic studies are needed to interpret beneficial clinical effects of the SGLT2 inhibitors. Based on studies demonstrating SGLT2 inhibitors' favorable effects on LV modeling, investigators hypothesize that SGLT2 inhibitor, ertugliflozin, is effective on improving MR in patients with functional MR secondary to LV dysfunction and try to examine this hypothesis in a multicenter, double-blind, randomized comparison study using echocardiography.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Mitral Valve Insufficiency, Left Ventricular Systolic Dysfunction

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
224 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
All patients will receive placebo in addition to their usual medications. Titration of HF medications should be completed and patients must take a stable, optimized dose of a β-blocker and an ACE inhibitor (or ARB) for at least 4 weeks prior to study entry.
Arm Title
Ertugliflozin
Arm Type
Active Comparator
Arm Description
All patients will receive ertugliflozin 5 mg qd in addition to their usual medications. Titration of HF medications should be completed and patients must take a stable, optimized dose of a β-blocker and an ACE inhibitor (or ARB) for at least 4 weeks prior to study entry.
Intervention Type
Drug
Intervention Name(s)
Ertugliflozin
Other Intervention Name(s)
Steglatro
Intervention Description
Ertugliflozin 5mg qd for 12 months
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo qd for 12 months
Primary Outcome Measure Information:
Title
Change of EROA
Description
Change of effective regurgitant orifice area (EROA) of functional mitral regurgitation
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Change of regurgitant volume
Description
Change of regurgitant volume of functional mitral regurgitation
Time Frame
12 months
Title
Change of end-systolic volume
Description
Change of left ventricular end-systolic volume
Time Frame
12 months
Title
Change of end-diastolic volume
Description
Change of left ventricular end-diastolic volume
Time Frame
12 months
Title
Change of NT-proBNP
Description
Change of NT-proBNP (N-terminal of the prohormone brain natriuretic peptide)
Time Frame
12 months
Title
Change of GLS
Description
Change of left ventricular global longitudinal strain
Time Frame
12 months
Title
Change of LA volume
Description
Change of left atrial volume index
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients must agree to the study protocol and provide written informed consent Outpatients ≥ 20 years of age, male or female Non-diabetic or type2 DM patients with HbA1c 7.0-10.5% Patients with secondary functional MR (stage B and C) and LV dysfunction Symptoms due to coronary ischemia or heart failure may be present but symptoms due to MR should be absent Normal mitral valve leaflets and chords Regional or global wall motion abnormalities with mild or severe tethering of leaflet MR whose ERO > 0.10 cm2 and which lasted > 6 months under medical treatment with a β-blocker and an ACE inhibitor (or ARB) 35% < LV ejection fraction < 50% Dyspnea of NYHA functional class II or III Titration of HF medications should be completed and patients must take a stable, optimized dose of a β-blocker and an ACE inhibitor (or ARB) for at least 4 weeks prior to study entry Exclusion Criteria: History of hypersensitivity or allergy to the study drug, drugs of similar chemical classes, or SGLT-2 as well as known or suspected contraindications to the study drug Current use or prior use of a SGLT-2 inhibitor or combined SGLT-1 and 2 inhibitor Known history of angioedema Any evidence of structural mitral valve disease, including prolapse of mitral leaflets and rupture of chords or papillary muscles Current acute decompensated heart failure or dyspnea of NYHA functional class IV Medical history of hospitalization within 6 weeks Symptomatic hypotension and/or a SBP < 100 mmHg at screening Estimated GFR < 45 mL/min/1.73m2 History of ketoacidosis Evidence of hepatic disease as determined by any one of the following: AST or ALT values exceeding 2 x upper limit of normal (ULN) at screening visit (Visit 0), history of hepatic encephalopathy, history of esophageal varices, or history of portacaval shunt. Acute coronary syndrome, stroke, major CV surgery, PCI within 3 months Substantial myocardial ischemia requiring coronary revascularization, a plan of coronary revascularization or mitral valve intervention within 1 year Indication of cardiac resynchronization therapy, a plan of heart transplantation or implantation of cardiac resynchronization therapy History of severe pulmonary disease Significant aortic valve disease Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using a barrier method plus a hormonal method Pregnant or nursing (lactating) women Any clinically significant abnormality identified at the screening visit, physical examination, laboratory tests, or electrocardiogram which, in the judgment of the investigator, would preclude safe completion of the study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
DUK HYUN KANG, MD
Organizational Affiliation
Asan Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Asan Medical Center
City
Seoul
Country
Korea, Republic of
Facility Name
Samsung Medical Center
City
Seoul
Country
Korea, Republic of
Facility Name
Seoul National University Hospital
City
Seoul
Country
Korea, Republic of

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Ertugliflozin for Functional Mitral Regurgitation

We'll reach out to this number within 24 hrs